On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
In response to several reported deaths, the FDA has issued a warning to alert health care providers of potential mortality risk related to intragastric balloon systems.
